Malvern Instruments completes MicroCal acquisition

MALVERN Instruments has completed the acquisition of MicroCal from GE Healthcare Life Sciences and has also purchased the Archimedes particle characterization system from Affinity Biosensors.

Both of these developments extend Malvern’s portfolio of analytical solutions for the rapidly advancing biopharmaceutical industry.
 
The agreement to purchase GE Healthcare Life Sciences’ MicroCal business – for an undisclosed amount – was announced on June 4 by the Great Malvern company’s parent company Spectris and completion follows regulatory approval of the transaction.

MicroCal microcalorimeters are now part of the Malvern Instruments portfolio and are being sold and supported by Malvern Instruments with immediate effect.

Users of MicroCal systems have been notified directly of any changes.
 
Malvern’s purchase of the Archimedes product from US firm Affinity Biosensors follows two years of highly successful collaborative working between the two companies.

In 2012, Malvern entered into an exclusive distribution agreement with Affinity Biosensors to market and sell Affinity Biosensors’ Archimedes particle characterization system in all areas outside of North America, with a co-marketing agreement for North America itself.

Malvern has now acquired the Archimedes product designs and IP and a licence to the underlying MIT patent for the technology for relevant fields of use.

With this complete, Archimedes becomes a fully Malvern owned product and will be supported by the Malvern teams worldwide.
 
Malvern’s managing director Paul Walker said:  “ MicroCal microcalorimeters are an exciting and important new addition to Malvern’s portfolio that will significantly extend our ability to serve customers working in pharmaceutical and biopharmaceutical discovery, development and formulation. 
 
“Affinity Biosensors’ Archimedes system has brought the technique of resonant mass measurement into our range, and its close fit within our biopharmaceutical offering has encouraged us to secure its place and future development within Malvern.

“As part of our analytical toolkit for the biopharmaceutical industry, Archimedes sits alongside Zetasizer and NanoSight nanoparticle tracking analysis systems, delivering a range of complementary solutions for quantifying early aggregation in bioformulations.“

Click here to sign up to receive our new South West business news...
Close